Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Active, not recruiting · Phase 4 · NCT03229200
Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
At a glance
- Research payments reported, 2025
- $143,968
- U.S. investigators named
- 22
- Sites paid
- 22
- Planned or actual enrollment
- 297
About the trial
- Sponsor
- Pharmacyclics Switzerland GmbH (with Janssen Biotech, Inc., including Johnson & Johnson)
- Tested
- Ibrutinib (drug)
- Dates
- Started 2017-05-22; completion 2027-05-10
- Results posted
- Not yet
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
From ClinicalTrials.gov, last updated 2025-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $143,968 in research payments for this study in 2025 (156 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sven De Vos, MD Hematology & Oncology · Los Angeles, CA
- Jason Gotlib, M.D., M.S. Hematology · Palo Alto, CA
- Thomas J. Kipps, M.D. Internal Medicine · La Jolla, CA
- Matthew G. Mei, M.D. Hematology · Duarte, CA
- Karlton Wong, MD Hematology & Oncology · Burbank, CA
- Nadia Khan, MD Hematology · Chicago, IL
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Jennifer R. Brown, MD PHD Hematology · Boston, MA
- Vrushali S. Dabak, M.D. Internal Medicine · Detroit, MI
- Nilanjan Ghosh, MD Medical Oncology · Charlotte, NC
- John N. Allan, M.D. Hematology & Oncology · New York, NY
- Jonathan Kolitz, MD Hematology & Oncology · Lake Success, NY
- Andrew D. Zelenetz, MD Medical Oncology · New York, NY
- Mark Knapp, MD Hematology & Oncology · Columbus, OH
- Tahir Latif, MD Hematology & Oncology · Cincinnati, OH
- Jason Valent, M.D. Hematology & Oncology · Strongsville, OH
- Jennifer A. Woyach, MD Hematology · Columbus, OH
- David Morgan, MD Medical Oncology · Nashville, TN
- Paolo Strati, M.D. Internal Medicine · Houston, TX
- William G. Wierda, M.D., PHD Hematology & Oncology · Houston, TX
- Siva K. Mannem, MD Hematology & Oncology · Yakima, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $34,649
- Providence Health System Southern C $26,535
- Weill Medical College of Cornell Un $17,880
- Ohio State University $11,639
- Ut MD Anderson Cancer Center $8,182
- UC Healthcare System $8,011
- Board of Trustees of the Leland Sta $7,613
- Memorial Sloan Kettering Cancer Cen $5,098
- Biomedical Research Alliance of New $4,456
- Henry Ford Health Hospital, MI $4,096
- Cleveland Clinic, OH $4,025
- Ronald Reagan UCLA Medical Center, CA $3,357
- Northwestern University $1,820
- Norton Hospitals, Inc, KY $1,730
- Atrium Health Union, NC $1,013
- Dana Farber PArtners Cancer Care in $984
- Yakima Valley Memorial, WA $876
- Swedish Medical Center, WA $743
- American Oncology PArtners PA $459
- Norton Healthcare Inc $326
- University of California Davis Medical Center, CA $261
- Vanderbilt University Medical Center, TN $215
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.